Caravaca F, Martín M V, Barroso S, Arrobas M, Ruiz-Calero R, García M C, Luna E, Sánchez-Casado E
Servicios de Nefrología, Hospital Infanta Cristina, Badajoz.
Nefrologia. 2004;24(5):453-62.
A protective effect of obesity on the mortality of end-stage renal failure patients has been observed in several studies. Most of these studies have been based on prevalent dialysis population. The aim of the present study was to evaluate if obesity has beneficial effects on the survival of advanced chronic renal failure patients. The study group consisted of 376 patients (mean age 63 +/- 15 years) with advanced chronic renal failure not yet on dialysis. Obesity was defined as a body mass index (BMI) > or = 30 kg/m2. Grade of comorbidity was quantified by the method devised by Davies. Survival was analyzed as time from the referral to the predialysis outpatient clinic to patient death, censoring from contributing additional survival data to the analysis following transplantation. Kaplan-Meier analysis was used to test survival differences according to quartiles of BMI, and between obese and nonobese patients. Further analysis were performed, stratifying survival curves by comorbid scores, lean body mass, age, and sex. Cox proportional hazard regression models were used to investigate the best determinants of mortality, and the role of obesity adjusted for other covariates. Median survival time was 1,453 days. During the follow-up time, 158 patients (42%) died. Survival differences among quartiles of BMI were statistically significant (Breslow = 10.7, p = 0.017). Patients within the lowest and the highest quartiles of BMI had higher mortality than the rest of patients. Survival curves between obese and non-obese patients did not differ significantly. However, when patients without comorbidity were studied apart, those with obesity showed worse survival than the rest of patients (log-rank = 7.42, p = 0.0064). Since the effect of obesity on mortality did not follow a proportional hazard pattern throughout the study period, multivariable analysis for mortality was stratified by 18 months intervals. The variables which fitted the best model were: age (Hazard Ratio: 1.04), comorbid score (HR: 2.17), serum albumin (HR: 0.62), GFR at the study entry (HR: 0.91), male gender (HR: 1.48), and obesity (HR: 1.51). In conclusion, obesity had no survival benefit in patients with advanced chronic renal failure. Obesity had a noteworthy impact on early mortality of advanced chronic kidney disease patients without comorbidities.
多项研究观察到肥胖对终末期肾衰竭患者的死亡率具有保护作用。这些研究大多基于现有的透析人群。本研究的目的是评估肥胖对晚期慢性肾衰竭患者的生存是否具有有益影响。研究组由376例尚未接受透析的晚期慢性肾衰竭患者组成(平均年龄63±15岁)。肥胖定义为体重指数(BMI)≥30kg/m²。合并症等级采用戴维斯设计的方法进行量化。生存分析为从转诊至透析前门诊到患者死亡的时间,在移植后为分析贡献额外生存数据时进行删失。采用Kaplan-Meier分析根据BMI四分位数以及肥胖和非肥胖患者来检验生存差异。进一步分析按合并症评分、瘦体重、年龄和性别对生存曲线进行分层。采用Cox比例风险回归模型研究死亡率的最佳决定因素以及调整其他协变量后肥胖的作用。中位生存时间为1453天。在随访期间,158例患者(42%)死亡。BMI四分位数之间的生存差异具有统计学意义(Breslow=10.7,p=0.017)。BMI最低和最高四分位数的患者死亡率高于其他患者。肥胖和非肥胖患者之间的生存曲线无显著差异。然而,当单独研究无合并症的患者时,肥胖患者的生存情况比其他患者更差(对数秩=7.42,p=0.0064)。由于在整个研究期间肥胖对死亡率的影响不遵循比例风险模式,因此对死亡率的多变量分析按18个月间隔进行分层。拟合最佳模型的变量为:年龄(风险比:1.04)、合并症评分(HR:2.17)、血清白蛋白(HR:0.62)、研究入组时的肾小球滤过率(HR:0.91)、男性(HR:1.48)和肥胖(HR:1.51)。总之,肥胖对晚期慢性肾衰竭患者的生存无益处。肥胖对无合并症的晚期慢性肾病患者的早期死亡率有显著影响。